Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Health US Lab Receives CLIA Certification

NEW YORK (GenomeWeb News) – Molecular Health today announced its US clinical laboratory has been CLIA-certified.

With the certification, the Woodlands, Texas-based facility will begin offering two tests. One is a targeted gene panel of more than 500 known cancer genes, and the other offers whole-exome sequencing of the tumor genome.

"Now that our certification is complete, we'll soon be able to begin receiving and analyzing samples in order to provide oncologists and pathologists with personalized information on their patients' tumors," Molecular Health Chief Medical Officer Shelly Gunn said in a statement.

Molecular Health announced the opening of its office in The Woodlands in January. The company was originally founded in Basel, Switzerland and its headquarters are now in Germany. The US office and lab occupies about 7,000-square-feet of space. The lab is being equipped with Illumina sequencers.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.